Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion

Abstract

Purpose : To report the outcome of intravitreal injection of 1.25 mg bevacizumab for macular edema secondary to branch retinal vein occlusion (BRVO). Cases and Method : This study was made on 22 eyes of 22 cases of BRVO. The series comprised 12 males and 10 females. The age ranged from 47 to 81 years, average 64 years. Results : After follow-up for 6 months or longer, visual acuity improved in 16 eyes, remained unchanged in 3, and deteriorated in 3. Final visual acuity was influenced by final central retinal thickness, initial status of junction between inner and outer photoreceptor segments, and recurrence of macular edema. Macular edema resolved in 6 eyes after one injection and recurred in 15 eyes after an average of 2.75 months, of which 10 eyes received an average of 2.5 injections. Recurrence tended to occur in cases under 65 years of age and in eyes treated within 3 months after onset. Conclusion : Intravitreal bevacizumab is effective for macular edema secondary to BRVO. Rinsho Ganka (Jpn J Clin Ophthalmol) 63(5): 683-687, 2009.